RBC Capital Resumes Coverage of Danaher Corporation (DHR)
RBC Capital has resumed coverage of Danaher Corporation with an Outperform rating and a price target of $200. The firm believes the company's growth will recover due to improvements in the bioprocess market and other factors. Danaher Corporation reported net earnings of $1.0 billion and revenues of $6.0 billion in its fiscal Q1 2026 financial results.
- ▪RBC Capital resumed coverage of Danaher Corporation with an Outperform rating on May 14
- ▪The company reported net earnings of $1.0 billion and revenues of $6.0 billion in its fiscal Q1 2026 financial results
- ▪Danaher Corporation operates through Diagnostics, Biotechnology, Life Sciences, and Environmental and Applied Solutions
Opening excerpt (first ~120 words) tap to expand
RBC Capital Resumes Coverage of Danaher Corporation (DHR) Noor Ul Ain Rehman Tue, May 26, 2026 at 5:43 AM PDT 1 min read DHR +0.47% Trade Danaher on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational. Learn more Danaher Corporation (NYSE:DHR) is one of the best medical stocks to invest in according to billionaires. RBC Capital resumed coverage of Danaher Corporation (NYSE:DHR) with an Outperform rating on May 14, setting a price target of $200.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Yahoo Finance.